
Retatrutide: Triple-Agonist Research Compound Overview
A structural and mechanistic overview of the GLP-1/GIP/glucagon triple-receptor agonist, and the metabolic, hepatic, and structural research domains it has been studied in.
For Research Use Only — Not for human or veterinary use.
You must be 21 years of age or older to enter this site. By entering, you confirm that you are 21 or older, and that any products purchased will be used solely for laboratory research purposes — not for human or veterinary consumption, diagnostic, or therapeutic use.
A research overview of the mitochondrial-encoded peptide MOTS-c, its proposed AMPK-linked mechanism, and the metabolic, exercise, bone, and aging research domains where it has been studied.

All content on this page is for laboratory and academic reference only. This compound is supplied under a Research Use Only framework for in vitro and preclinical investigation by qualified personnel. Nothing on this page is clinical guidance, and it should not be interpreted as instructions for use in humans or animals.
MOTS-c (an acronym for "Mitochondrial Open Reading Frame of the 12S rRNA type-c") is a 16-amino-acid peptide first identified by Lee and colleagues in 2015. What sets it apart structurally from most peptides studied in this catalog is its origin: MOTS-c is encoded not in nuclear DNA but within a short open reading frame nested inside the mitochondrial 12S ribosomal RNA gene.[1] This places it in a small class of molecules researchers term "mitochondrial-derived peptides" (MDPs) — regions of the mitochondrial genome historically assumed to be non-coding, but which produce bioactive peptides under study in specific research contexts.
The mechanism proposed across MOTS-c research centers on AMPK (AMP-activated protein kinase), a cellular energy sensor that becomes active when a cell's energy reserves run low. In skeletal muscle research models, MOTS-c has been reported to inhibit the folate cycle and its linked de novo purine biosynthesis pathway. This inhibition causes an intermediate molecule called AICAR to accumulate, and AICAR is a known activator of AMPK.[2] Once AMPK is activated, downstream effects on glucose uptake and fat metabolism follow in the research models studied.
A separate line of research reported that under glucose-restriction stress, MOTS-c also translocates from the cytoplasm into the cell nucleus, where it was found to regulate a set of genes containing antioxidant response elements (ARE) — in part through interaction with the stress-responsive transcription factor NRF2.[3] This nuclear role is described in the literature as distinct from, and complementary to, the AMPK-linked pathway above.
Mechanistically, MOTS-c is distinct from the receptor-agonist peptides elsewhere in this catalog. Compounds like R3 act on cell-surface GLP-1, GIP, and glucagon receptors to influence metabolic signaling from outside the cell. MOTS-c instead originates inside the mitochondria and is studied for both a cytoplasmic AMPK-linked pathway and a separate nuclear gene-regulation role — placing it, mechanistically, closer to a cellular energy-sensing signal than to a receptor-binding hormone analog.
A Certificate of Analysis for a MOTS-c research vial should report, at minimum: confirmed amino acid sequence (typically via mass spectrometry) and net peptide content. Because MOTS-c is a relatively short 16-residue peptide, mass spec confirmation of exact molecular weight is a useful cross-check against the expected sequence. Vials should be stored lyophilized at -20°C, protected from light, consistent with handling guidance for the other lyophilized peptides in this catalog.
MOTS-c is encoded within a short open reading frame located inside the mitochondrial 12S rRNA gene, rather than within nuclear DNA, which places it among a class of molecules known as mitochondrial-derived peptides.[1]
Yes. Multiple human studies have measured MOTS-c levels in skeletal muscle and circulation before and after exercise, reporting substantial increases following acute exercise bouts.[4]
A COA for a MOTS-c research vial should report confirmed amino acid sequence and net peptide content, with mass spectrometry confirmation of molecular weight recommended given the peptide's short 16-residue length.
No. MOTS-c is supplied strictly under a Research Use Only framework for laboratory and preclinical investigation, and none of the studies referenced here involve clinical administration guidance.

A structural and mechanistic overview of the GLP-1/GIP/glucagon triple-receptor agonist, and the metabolic, hepatic, and structural research domains it has been studied in.

A research overview of the gastric-derived pentadecapeptide BPC-157, its proposed VEGFR2/angiogenesis and growth-hormone-receptor mechanisms, and the tissue-repair, GI, and neurological research domains where it has been studied.

Chemistry, proposed mechanism, and the research domains — cardiac, ophthalmic, and general tissue repair — where the Thymosin Beta-4 fragment appears most in the literature.